|
|
 |
|
Viewing report
|
|
|
|
U.S. Pulmonary Arterial Hypertension Markets
Frost & Sullivan, Dec 2006, Pages: 104
This research service covers the U.S. pulmonary arterial hypertension (PAH) markets and includes the four classes of PAH according to the New York Heart Association classification. The research service provides a market overview, competitive structure, market forecasts and market share analysis across these four segments.
Market Sectors
Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
-Total U.S. PAH therapy
-Class I PAH therapy
-Class II PAH therapy
-Class III PAH therapy
-Class IV PAH therapy
'Big Pharma' and Biotechnology Companies Boost U.S. Pulmonary Arterial Hypertension Markets
The U.S. pulmonary arterial hypertension (PAH) markets have been growing due to the launch of new therapies as well as keen interest shown by 'Big Pharma' and biotechnology companies. A small patient population notwithstanding, the market is expected to grow rapidly. 'The development of a strong clinical pipeline with two major launches in 2007, and improvement in diagnosis rates are likely to drive market growth,' says the analyst of this research service.
The number of treatment options available for this condition has grown considerably over the past few years with new therapies expected. The granting of orphan drug status has encouraged the development of drugs, which would have been cost-prohibitive and unprofitable under normal circumstances. 'Big Pharma' companies are focusing on this therapeutic area despite the orphan drug status. With increasing awareness of the disease and introduction of better treatment options, diagnosis rates are expected to rise further.
In-licensing Deals and Mergers and Acquisitions Spur Strong Growth
An increase in in-licensing and M&A deals in the PAH markets is also leveraging growth. 'The market has drawn interest from 'Big Pharma' and biotechnology companies partly due to the high reimbursement rates and average revenue per patient,' states the analyst. Therefore, companies are looking to enter into the market through mergers and acquisitions or licensing of clinical stage products.
The key competitive factors include efficacy, convenience of dosing, and side effect profiles of therapies. The progression of PAH is rapid and the mortality rates are extremely high with most patients surviving for less than 3-4 years post diagnosis. Hence, the efficacy of a drug to slow down the progression of the disease, coupled with convenience of dosing is the prime competitive factor.
Customers who bought this item also bought
Stakeholder Opinions: Pulmonary Arterial Hypertension clinical community builds order from chaos
Stakeholder Perspectives: Pulmonary Arterial Hypertension - A Small Market Gets Big Attention
Pulmonary Arterial Hypertension: Diagnosis and Evidence-Based Treatment
New Therapies for Pulmonary Arterial Hypertension: Orphan Drugs Seeking Opportunities in Wider Related Indications
Strategic Analysis of the Kenyan Hypertension Markets
Handbook of Hypertension
Chinese Markets for Hypertension Drugs
China Hypertension Drug Market 2008
Pulmonary Drug Delivery Technologies - Global Strategic Business Report
Pulmonary Hypertension: New Potential in a Limited Market
Hypertension - Multiple Layers of Therapy Cover all Eventualities
Disease and Therapy Review: Hypertension
|
|
|
|
